CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.161485
0.000000 (0.000000%)
As of 2:41PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.161485
Open0.000000
Bid0.000000 x 0
Ask0.000000 x 0
Day's Range0.000000 - 0.000000
52 Week Range
Volume0
Avg. Volume6,436
Market Cap7.112M
Beta-2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.023000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile22 days ago

    Cell MedX Corp. provides additional information on its observational clinical trial with diabetes and related conditions

    Carson City, Nevada--(Newsfile Corp. - January 30, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), is an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. As reported in a news releases issued by the Company on January 24, 2018, an observational clinical trial was completed by Dr. Richard Tytus and his team at Hamilton Medical ...

  • Newsfile23 days ago

    Cell MedX Corp. Assigned Legal Entity Identifier Number by Deutsche Börse Group

    Carson City, Nevada--(Newsfile Corp. - January 29, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX:MUN), ("Cell MedX" or the "Company"), announces that it has been assigned a Legal Entity Identifier number 967600RJ7LKTH79OWE67. About the Legal Entity Identifier Number ("LEI")The European Union has adopted regulations that require use of the LEI as a barcode equivalent aimed at pinpointing systemic risks. The LEI is a 20-digit alphanumeric code that is an internationally standardized and globally valid ...

  • Newsfile28 days ago

    Cell MedX Corp. completes its first observational clinical trial and observes positive results with diabetes and related conditions

    Carson City, Nevada--(Newsfile Corp. - January 24, 2018) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the observational clinical trial carried out by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario (the "Trial") has been completed. Nutrasource Diagnostics ...

  • Newsfile3 months ago

    Cell MedX Corp. Appoints Dr. Terrance Owen as CEO and Director

    Carson City, Nevada--(Newsfile Corp. - December 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has appointed Dr. Terrance Owen to the Board of Directors and as Chief Executive Officer. Dr. Owen replaces Mr. McEnulty, as CEO of the Company. Mr. McEnulty ...

  • Newsfile4 months ago

    Cell MedX Corp. Closes the First Tranche of Its Non-Brokered Private Placement Financing, Converts Debt

    Carson City, Nevada--(Newsfile Corp. - October 19, 2017) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on October 12, 2017, the Company closed the first tranche of its non-brokered private placement offering (the "Offering") at a price of $0.25 per unit (the "Unit"), by ...

  • Newsfile6 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - August 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with the corporate update on its current operations. Private PlacementThe Company's board of directors has approved a private placement offering of up to 8,000,000 units of the ...

  • Newsfile7 months ago

    Cell MedX Corp. Provides Update on its Clinical Observational Trial

    Carson City, Nevada--(Newsfile Corp. - July 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that all 30 subjects taking part in the Company's ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") have ...

  • Newsfile8 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - July 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that its currently ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") is nearing its completion. To date, 29 ...

  • Cell MedX Corp. :CMXC-US: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017
    Capital Cube9 months ago

    Cell MedX Corp. :CMXC-US: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017

    Categories: Yahoo FinanceGet free summary analysis Cell MedX Corp. reports financial results for the quarter ended February 28, 2017. We analyze the earnings along side the following peers of Cell MedX Corp. – Town Sports International Holdings, Inc. (CLUB-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of ... Read more (Read more...)

  • Accesswire10 months ago

    Cell MedX Corp. Moves its Manufacturing to British Columbia, Canada

    CARSON CITY, NV / ACCESSWIRE / April 26, 2017 / Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), is pleased to announce that the Company's Canadian subsidiary has entered ...

  • Accesswire11 months ago

    Cell MedX Corp. Announces FDA Registration and Update on Clinical Observational Study

    CARSON CITY, NV / ACCESSWIRE / March 28, 2017 / Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), announced that it has completed its registration process with U.S. Food ...

  • Accesswire11 months ago

    Cell MedX Corp. Announces First Subjects Screened and Qualified for the Observational Clinical Trial

    CARSON CITY, NV / ACCESSWIRE / March 9, 2017 / Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), is pleased to announce that Dr. Richard Tytus, the Lead Investigator on ...

  • Accesswirelast year

    Cell MedX Corp. Receives Approval from Ethics Review Board to Commence its Observational Clinical Trial in Canada for Type 1 and Type 2 Diabetics

    CARSON CITY, NV / ACCESSWIRE / March 1, 2017 / Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), is happy to announce that it has received an approval from ...

  • Accesswirelast year

    Cell MedX Corp. Engages Think Ink Marketing

    CARSON CITY, NV / ACCESSWIRE / February 24, 2017 / Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, ...